Multiple Myeloma — Trials

Multiple Myeloma — Trials · CancerIndex

Clinical trials

Registered studies

3,384 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 814
Recruiting: 414
Ph III recruiting: 54
Growth YoY: +13.3%
Industry share: 29%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34%
Trials / 1,000 deaths: 70.3 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (536)

clinicaltrialsPublishedShowing 301–307 of 307 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04808037	Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma(BelaRd)	active not recruiting	Phase 1 / Phase 2	66	Hellenic Society of HematologyOTHER	1	Oct 24, 2023	clinicaltrials
NCT04613557	Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma(IMMUNICY-1)	active not recruiting	Phase 1	18	Celyad Oncology SAINDUSTRY